{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:43:51Z","timestamp":1793259831401,"version":"4.5.0"},"reference-count":101,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:sec id=\"ab-jrv220019-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Anxiety disorders have a lifetime prevalence of approximately 34% in the US, are often chronic, and significantly impair quality of life and functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv220019-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Anxiety disorders are characterized by symptoms that include worry, social and performance fears, unexpected and\/or triggered panic attacks, anticipatory anxiety, and avoidance behaviors. Generalized anxiety disorder (6.2% lifetime prevalence), social anxiety disorder (13% lifetime prevalence), and panic disorder (5.2% lifetime prevalence) with or without agoraphobia are common anxiety disorders seen in primary care. Anxiety disorders are associated with physical symptoms, such as palpitations, shortness of breath, and dizziness. Brief screening measures applied in primary care, such as the Generalized Anxiety Disorder\u20137, can aid in diagnosis of anxiety disorders (sensitivity, 57.6% to 93.9%; specificity, 61% to 97%). Providing information about symptoms, diagnosis, and evidence-based treatments is a first step in helping patients with anxiety. First-line treatments include pharmacotherapy and psychotherapy. Selective serotonin reuptake inhibitors (SSRIs, eg, sertraline) and serotonin-norepinephrine reuptake inhibitors (SNRIs, eg, venlafaxine extended release) remain first-line pharmacotherapy for generalized anxiety disorder, social anxiety disorder, and panic disorder. Meta-analyses suggest that SSRIs and SNRIs are associated with small to medium effect sizes compared with placebo (eg, generalized anxiety disorder: standardized mean difference [SMD], \u22120.55 [95% CI, \u22120.64 to \u22120.46]; social anxiety disorder: SMD, \u22120.67 [95% CI, \u22120.76 to \u22120.58]; panic disorder: SMD, \u22120.30 [95% CI, \u22120.37 to \u22120.23]). Cognitive behavioral therapy is the psychotherapy with the most evidence of efficacy for anxiety disorders compared with psychological or pill placebo (eg, generalized anxiety disorder: Hedges g\u2009=\u20091.01 [large effect size] [95% CI, 0.44 to 1.57]; social anxiety disorder: Hedges g\u2009=\u20090.41 [small to medium effect] [95% CI, 0.25 to 0.57]; panic disorder: Hedges g\u2009=\u20090.39 [small to medium effect[ [95% CI, 0.12 to 0.65]), including in primary care. When selecting treatment, clinicians should consider patient preference, current and prior treatments, medical and psychiatric comorbid illnesses, age, sex, and reproductive planning, as well as cost and access to care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv220019-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Anxiety disorders affect approximately 34% of adults during their lifetime in the US and are associated with significant distress and impairment. First-line treatments for anxiety disorders include cognitive behavioral therapy, SSRIs such as sertraline, and SNRIs such as venlafaxine extended release.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2022.22744","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T11:01:13Z","timestamp":1672138873000},"page":"2431","source":"Crossref","is-referenced-by-count":554,"title":["Anxiety Disorders"],"prefix":"10.1001","volume":"328","author":[{"given":"Kristin L.","family":"Szuhany","sequence":"first","affiliation":[{"name":"Department of Psychiatry, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi M.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jrv220019r1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12532","article-title":"Treatment of common mental disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.","volume":"80","author":"Olfson","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"jrv220019r2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"issue":"3","key":"jrv220019r3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century.","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"key":"jrv220019r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110207","article-title":"Prevalence of anxiety in the COVID-19 pandemic: an updated meta-analysis of community-based studies.","volume":"109","author":"Santab\u00e1rbara","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10100","key":"jrv220019r5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"jrv220019r8","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.10m01013","article-title":"Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study.","volume":"13","author":"Vermani","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"issue":"5","key":"jrv220019r9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","article-title":"Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.","volume":"146","author":"Kroenke","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"jrv220019r10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/da.2015.32.issue-7","article-title":"Detection of anxiety disorders in primary care: a meta-analysis of assisted and unassisted diagnoses.","volume":"32","author":"Olariu","year":"2015","journal-title":"Depress Anxiety"},{"issue":"3","key":"jrv220019r11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1742-9536.2011.00037.x","article-title":"The statistical recommendations of the American Psychological Association publication manual: effect sizes, confidence intervals, and meta-analysis.","volume":"64","author":"Cumming","year":"2012","journal-title":"Aust J Psychol"},{"issue":"2","key":"jrv220019r12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders.","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"issue":"6","key":"jrv220019r15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1176\/ps.2010.61.6.624","article-title":"Diagnosis and treatment of depression and anxiety in rural and nonrural primary care: national survey results.","volume":"61","author":"Jameson","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"Suppl 1","key":"jrv220019r16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"12","key":"jrv220019r17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/0004867418799453","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder.","volume":"52","author":"Andrews","year":"2018","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"jrv220019r18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.","volume":"28","author":"Baldwin","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"2","key":"jrv220019r19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int J Psychiatry Clin Pract"},{"key":"jrv220019r21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1471-2288-11-154","article-title":"A population study comparing screening performance of prototypes for depression and anxiety with standard scales.","volume":"11","author":"Christensen","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"jrv220019r22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11606-017-4181-0","article-title":"Screening for behavioral health conditions in primary care settings: a systematic review of the literature.","volume":"33","author":"Mulvaney-Day","year":"2018","journal-title":"J Gen Intern Med"},{"key":"jrv220019r23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.genhosppsych.2015.11.005","article-title":"Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic meta-analysis.","volume":"39","author":"Plummer","year":"2016","journal-title":"Gen Hosp Psychiatry"},{"issue":"10","key":"jrv220019r24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"jrv220019r25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/da.v26:1","article-title":"Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale.","volume":"26","author":"Rytwinski","year":"2009","journal-title":"Depress Anxiety"},{"issue":"3","key":"jrv220019r26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/cpp.v25.3","article-title":"Liebowitz Social Anxiety Scale (LSAS): optimal cut points for remission and response in a German sample.","volume":"25","author":"von Glischinski","year":"2018","journal-title":"Clin Psychol Psychother"},{"key":"jrv220019r27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1192\/bjp.176.4.379","article-title":"Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale.","volume":"176","author":"Connor","year":"2000","journal-title":"Br J Psychiatry"},{"issue":"2","key":"jrv220019r28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(ISSN)1520-6394","article-title":"Mini-SPIN: a brief screening assessment for generalized social anxiety disorder.","volume":"14","author":"Connor","year":"2001","journal-title":"Depress Anxiety"},{"key":"jrv220019r29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jad.2019.07.057","article-title":"Development of a very brief scale for detecting and measuring panic disorder using two items from the Panic Disorder Severity Scale-Self Report.","volume":"257","author":"Forsell","year":"2019","journal-title":"J Affect Disord"},{"issue":"5","key":"jrv220019r30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0022-3956(01)00028-0","article-title":"Reliability and validity of the Panic Disorder Severity Scale: replication and extension.","volume":"35","author":"Shear","year":"2001","journal-title":"J Psychiatr Res"},{"issue":"9","key":"jrv220019r31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"2","key":"jrv220019r32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1192\/bjpo.bp.115.001685","article-title":"Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies.","volume":"2","author":"Mitchell","year":"2016","journal-title":"BJPsych Open"},{"key":"jrv220019r33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jad.2018.01.030","article-title":"A computerized version of the Patient Health Questionnaire-4 as an ultra-brief screening tool to detect emotional disorders in primary care.","volume":"234","author":"Cano-Vindel","year":"2018","journal-title":"J Affect Disord"},{"issue":"1-3","key":"jrv220019r34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jad.2008.03.014","article-title":"Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS).","volume":"112","author":"Campbell-Sills","year":"2009","journal-title":"J Affect Disord"},{"issue":"7","key":"jrv220019r35","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.janxdis.2014.07.006","article-title":"Identification of anxiety sensitivity classes and clinical cut-scores in a sample of adult smokers: results from a factor mixture model.","volume":"28","author":"Allan","year":"2014","journal-title":"J Anxiety Disord"},{"issue":"1","key":"jrv220019r36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7326\/M20-0580","article-title":"Screening for anxiety in adolescent and adult women: a recommendation from the Women\u2019s Preventive Services Initiative.","volume":"173","author":"Gregory","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"jrv220019r38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jama.2014.5950","article-title":"Does this patient have generalized anxiety or panic disorder? the Rational Clinical Examination systematic review.","volume":"312","author":"Herr","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"jrv220019r39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4088\/PCC.v03n0609","article-title":"The comorbidity of major depression and anxiety disorders: recognition and management in primary care.","volume":"3","author":"Hirschfeld","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"5","key":"jrv220019r40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1176\/appi.ajp.2020.20030305","article-title":"The critical relationship between anxiety and depression.","volume":"177","author":"Kalin","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"8","key":"jrv220019r41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"61","author":"Grant","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"27-28","key":"jrv220019r46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3238\/arztebl.2014.0473","article-title":"The diagnosis of and treatment recommendations for anxiety disorders.","volume":"111","author":"Bandelow","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"jrv220019r47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: a meta-analysis.","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"jrv220019r48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/0269881117699361","article-title":"British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.","volume":"31","author":"McAllister-Williams","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"6","key":"jrv220019r49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003664","article-title":"Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: a 3-level network meta-analysis.","volume":"18","author":"Gosmann","year":"2021","journal-title":"PLoS Med"},{"key":"jrv220019r50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jpsychires.2019.08.014","article-title":"Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis.","volume":"118","author":"Chen","year":"2019","journal-title":"J Psychiatr Res"},{"key":"jrv220019r51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066084","article-title":"Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials.","volume":"376","author":"Chawla","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"jrv220019r52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001206.pub3","article-title":"Pharmacotherapy for social anxiety disorder (SAnD).","volume":"10","author":"Williams","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"jrv220019r53","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? a systematic review.","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"jrv220019r54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008120.pub2","article-title":"Second-generation antipsychotics for anxiety disorders.","author":"Depping","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"jrv220019r58","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/da.2019.36.issue-3","article-title":"Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders.","volume":"36","author":"Jakubovski","year":"2019","journal-title":"Depress Anxiety"},{"key":"jrv220019r59","doi-asserted-by":"publisher","first-page":"j3927","DOI":"10.1136\/bmj.j3927","article-title":"Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials.","volume":"358","author":"Batelaan","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"jrv220019r60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States.","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"jrv220019r61","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000870","article-title":"Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a bayesian hierarchical modeling meta-analysis.","author":"Stimpfl","journal-title":"CNS Spectr"},{"issue":"3","key":"jrv220019r62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010677.pub2","article-title":"Benzodiazepines versus placebo for panic disorder in adults.","volume":"3","author":"Breilmann","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"jrv220019r63","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"jrv220019r64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines.","volume":"49","author":"Jones","year":"2015","journal-title":"Am J Prev Med"},{"issue":"5","key":"jrv220019r67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/YIC.0000000000000276","article-title":"Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis.","volume":"34","author":"Shinfuku","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"jrv220019r69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006115","article-title":"Azapirones for generalized anxiety disorder.","volume":"2006","author":"Chessick","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"jrv220019r70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006815.pub2","article-title":"Hydroxyzine for generalised anxiety disorder.","author":"Guaiana","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"jrv220019r71","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/JCP.0b013e31821b2b3f","article-title":"Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis.","volume":"31","author":"LaLonde","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"jrv220019r72","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis.","volume":"30","author":"Steenen","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"6","key":"jrv220019r73","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/da.2018.35.issue-6","article-title":"Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials.","volume":"35","author":"Carpenter","year":"2018","journal-title":"Depress Anxiety"},{"issue":"6","key":"jrv220019r74","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10865-019-00046-z","article-title":"Cognitive behavioral therapy for primary care depression and anxiety: a secondary meta-analytic review using robust variance estimation in meta-regression.","volume":"42","author":"Zhang","year":"2019","journal-title":"J Behav Med"},{"key":"jrv220019r75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.janxdis.2018.01.001","article-title":"Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis.","volume":"55","author":"Andrews","year":"2018","journal-title":"J Anxiety Disord"},{"issue":"4","key":"jrv220019r76","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.psc.2017.08.007","article-title":"Can cognitive behavioral therapy for anxiety and depression be improved with pharmacotherapy? a meta-analysis.","volume":"40","author":"Tolin","year":"2017","journal-title":"Psychiatr Clin North Am"},{"issue":"2","key":"jrv220019r77","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cpr.2014.01.002","article-title":"Psychological treatment of generalized anxiety disorder: a meta-analysis.","volume":"34","author":"Cuijpers","year":"2014","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"jrv220019r78","doi-asserted-by":"publisher","first-page":"20385","DOI":"10.1038\/s41598-021-99882-w","article-title":"A systematic review and meta-analysis of acceptance- and mindfulness-based interventions for DSM-5 anxiety disorders.","volume":"11","author":"Haller","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"jrv220019r79","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1176\/ajp.2007.164.2.265","article-title":"A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder.","volume":"164","author":"Milrod","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"7","key":"jrv220019r80","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4088\/JCP.14m09507","article-title":"Psychotherapies for panic disorder: a tale of two sites.","volume":"77","author":"Milrod","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"jrv220019r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114046","article-title":"The anxiolytic effects of exercise for people with anxiety and related disorders: an update of the available meta-analytic evidence.","volume":"302","author":"Ramos-Sanchez","year":"2021","journal-title":"Psychiatry Res"},{"issue":"9","key":"jrv220019r82","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/da.2018.35.issue-9","article-title":"Yoga for anxiety: a systematic review and meta-analysis of randomized controlled trials.","volume":"35","author":"Cramer","year":"2018","journal-title":"Depress Anxiety"},{"issue":"3","key":"jrv220019r84","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamapsychiatry.2019.3986","article-title":"Long-term outcomes of cognitive behavioral therapy for anxiety-related disorders: a systematic review and meta-analysis.","volume":"77","author":"van Dis","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"jrv220019r85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2019.101751","article-title":"A systematic review and meta-analysis of the Unified Protocol as a transdiagnostic emotion regulation based intervention.","volume":"72","author":"Sakiris","year":"2019","journal-title":"Clin Psychol Rev"},{"issue":"5","key":"jrv220019r86","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0005-7967(87)90017-9","article-title":"Applied relaxation: description of a coping technique and review of controlled studies.","volume":"25","author":"Ost","year":"1987","journal-title":"Behav Res Ther"},{"issue":"7","key":"jrv220019r87","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cpr.2010.03.001","article-title":"Psychological flexibility as a fundamental aspect of health.","volume":"30","author":"Kashdan","year":"2010","journal-title":"Clin Psychol Rev"},{"issue":"4","key":"jrv220019r88","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/16506073.2015.1015163","article-title":"Running as interoceptive exposure for decreasing anxiety sensitivity: replication and extension.","volume":"44","author":"Sabourin","year":"2015","journal-title":"Cogn Behav Ther"},{"issue":"1","key":"jrv220019r89","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1192\/bjp.bp.115.166124","article-title":"Mindfulness-based cognitive therapy v group psychoeducation for people with generalised anxiety disorder: randomised controlled trial.","volume":"209","author":"Wong","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"8","key":"jrv220019r90","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4088\/JCP.12m08083","article-title":"Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity.","volume":"74","author":"Hoge","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"jrv220019r91","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.3679","article-title":"Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a randomized clinical trial.","author":"Hoge","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"jrv220019r92","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1017\/S0033291711000900","article-title":"The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review.","volume":"41","author":"Coull","year":"2011","journal-title":"Psychol Med"},{"issue":"1","key":"jrv220019r93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cpr.2010.09.008","article-title":"A review of technology-assisted self-help and minimal contact therapies for anxiety and depression: is human contact necessary for therapeutic efficacy?","volume":"31","author":"Newman","year":"2011","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"jrv220019r94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1192\/bjp.bp.110.084756","article-title":"Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review.","volume":"200","author":"Lewis","year":"2012","journal-title":"Br J Psychiatry"},{"key":"jrv220019r95","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.726222","article-title":"Digital interventions for generalized anxiety disorder (GAD): systematic review and network meta-analysis.","volume":"12","author":"Saramago","year":"2021","journal-title":"Front Psychiatry"},{"key":"jrv220019r96","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41746-019-0129-6","article-title":"By the numbers: ratings and utilization of behavioral health mobile applications.","volume":"2","author":"Carlo","year":"2019","journal-title":"NPJ Digit Med"},{"issue":"6","key":"jrv220019r97","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","article-title":"Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study.","volume":"162","author":"Bruce","year":"2005","journal-title":"Am J Psychiatry"},{"key":"jrv220019r98","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","article-title":"Response rates for CBT for anxiety disorders: need for standardized criteria.","volume":"42","author":"Loerinc","year":"2015","journal-title":"Clin Psychol Rev"},{"key":"jrv220019r99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpr.2018.03.002","article-title":"Remission in CBT for adult anxiety disorders: a meta-analysis.","volume":"61","author":"Springer","year":"2018","journal-title":"Clin Psychol Rev"},{"key":"jrv220019r100","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2021.102407","article-title":"A meta-analysis of relapse rates in cognitive-behavioral therapy for anxiety disorders.","volume":"81","author":"Levy","year":"2021","journal-title":"J Anxiety Disord"},{"issue":"4","key":"jrv220019r101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676.pub2","article-title":"Antidepressants versus placebo for panic disorder in adults.","volume":"4","author":"Bighelli","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"jrv220019r6","doi-asserted-by":"crossref","DOI":"10.4324\/9781315595009","volume-title":"Mental Illness in the Workplace: Psychological Disability Management","author":"Harder","year":"2016"},{"key":"jrv220019r7","first-page":"81","volume-title":"Comorbidity of Mental and Physical Illness: A Selective Review","author":"Kariuki-Nyuthe","year":"2015"},{"key":"jrv220019r14","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"jrv220019r20","volume-title":"Practice Guideline for the Treatment of Patients With Panic Disorder","author":"Stein","year":"2010"},{"key":"jrv220019r42","volume-title":"Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care","author":"National Collaborating Centre for Mental Health","year":"2011"},{"key":"jrv220019r43","volume-title":"Social Anxiety Disorder: Recognition, Assessment and Treatment","author":"National Collaborating Centre for Mental Health","year":"2013"},{"key":"jrv220019r45","author":"Roy-Byrne"},{"key":"jrv220019r83","author":"Hofmann"},{"key":"jrv220019r13","unstructured":"World Health Organization. ICD-11: International Classification of Diseases 11th Revision. Accessed October 20, 2022. https:\/\/icd.who.int\/"},{"key":"jrv220019r37","unstructured":"US Preventive Task Force. Screening for anxiety in adults. Accessed October 20, 2022. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/draft-recommendation\/anxiety-adults-screening"},{"key":"jrv220019r44","unstructured":"Baldwin? D. Generalized anxiety disorder in adults: epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis. In: Stein MB, ed. UpToDate. Accessed September 8, 2022. https:\/\/www.uptodate.com\/contents\/generalized-anxiety-disorder-in-adults-epidemiology-pathogenesis-clinical-manifestations-course-assessment-and-diagnosis"},{"key":"jrv220019r55","unstructured":"Craske? MG, Bystritsky? A. Generalized anxiety disorder in adults: management. In: Stein MB, ed. UpToDate. Accessed September 8, 2022. https:\/\/www.uptodate.com\/contents\/generalized-anxiety-disorder-in-adults-management"},{"key":"jrv220019r56","unstructured":"Roy-Byrne? P, Craske? MG. Management of panic disorder with or without agoraphobia in adults. In: Stein MB, ed. UpToDate. Accessed September 8, 2022. https:\/\/www.uptodate.com\/contents\/management-of-panic-disorder-with-or-without-agoraphobia-in-adults"},{"key":"jrv220019r57","unstructured":"Stein? MB. Pharmacotherapy for social anxiety disorder in adults. In: Roy-Byrne PP, ed. UpToDate. Accessed September 8, 2022. https:\/\/www.uptodate.com\/contents\/pharmacotherapy-for-social-anxiety-disorder-in-adults"},{"key":"jrv220019r65","unstructured":"Powers? M, Becker? E, Gorman? J, Kissen? D, Smits? J. Clinical practice review for GAD. Anxiety and Depression Association of America. Accessed October 20, 2022. https:\/\/adaa.org\/resources-professionals\/practice-guidelines-gad"},{"key":"jrv220019r66","unstructured":"Van Ameringen? M, Heimberg? RG, Schneier? F, Shannon? J, Stein? DJ. Clinical practice review for social anxiety disorder. Anxiety and Depression Association of America. Accessed October 20, 2022. https:\/\/adaa.org\/resources-professionals\/clinical-practice-review-social-anxiety"},{"key":"jrv220019r68","unstructured":"Hirsch? M, Birnbaum? RJ. Tricyclic and tetracyclic drugs: pharmacology, administration, and side effects. In: Roy-Byrne PP, ed. UpToDate. Accessed September 8, 2022. https:\/\/www.uptodate.com\/contents\/tricyclic-and-tetracyclic-drugs-pharmacology-administration-and-side-effects"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2799904\/jama_szuhany_2022_rv_220019_1671488975.84463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T11:01:23Z","timestamp":1672138883000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2799904"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":101,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.22744","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}